Load-mediated downregulation of myostatin mRNA is not sufficient to promote myofiber hypertrophy in humans: a cluster analysis
Open Access
- 1 November 2007
- journal article
- research article
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 103 (5), 1488-1495
- https://doi.org/10.1152/japplphysiol.01194.2006
Abstract
Myostatin is a potent inhibitor of myogenesis; thus differential expression might be expected across individuals varying in responsiveness to myogenic stimuli. We hypothesized that myostatin would be differentially regulated across humans with markedly different hypertrophic responses to resistance training (RT; 16 wk). Targets were assessed in muscle biopsies at baseline (T1) and 24 h after the first (T2) and last (T3) loading bouts in previously untrained subjects statistically clustered based on mean myofiber hypertrophy as extreme (Xtr; n = 17, 2,475 μm2), modest ( n = 32, 1,111 μm2), and nonresponders ( n = 17, −16 μm2). We assessed protein levels of latent full-length myostatin protein complex and its propeptide; mRNA levels of myostatin, cyclin D1, p21cip1, p27kip1, and activin receptor IIB; and serum myostatin protein concentration. Total RNA concentration increased by T3 in nonresponders (37%) and modest responders (40%), while it increased acutely (T2) only in Xtr (26%), remaining elevated at T3 (40%). Myostatin mRNA decreased at T2 (−44%) and remained suppressed at T3 (−52%), but not differentially across clusters. Cyclin D1 mRNA increased robustly by T2 (38%) and T3 (74%). The increase at T2 was driven by Xtr (62%, P < 0.005), and Xtr had the largest elevation at T3 (82%, P < 0.001). No effects were found for other target transcripts. Myostatin protein complex increased 44% by T3 ( P < 0.001), but not differentially by cluster. Myostatin protein complex propeptide and circulating myostatin were not influenced by RT or cluster. Overall, we found no compelling evidence that myostatin is differentially regulated in humans demonstrating robust RT-mediated myofiber hypertrophy vs. those more resistant to growth.Keywords
This publication has 54 references indexed in Scilit:
- Myostatin Induces Cyclin D1 Degradation to Cause Cell Cycle Arrest through a Phosphatidylinositol 3-Kinase/AKT/GSK-3β Pathway and Is Antagonized by Insulin-like Growth Factor 1Published by Elsevier BV ,2007
- Efficacy of myonuclear addition may explain differential myofiber growth among resistance-trained young and older men and womenAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- Interaction of contractile activity and training history on mRNA abundance in skeletal muscle from trained athletesAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- Aging-sensitive cellular and molecular mechanisms associated with skeletal muscle hypertrophyJournal of Applied Physiology, 2006
- Early signaling responses to divergent exercise stimuli in skeletal muscle from well‐trained humansThe FASEB Journal, 2005
- Myostatin auto‐regulates its expression by feedback loop through Smad7 dependent mechanismJournal of Cellular Physiology, 2005
- Time course of molecular responses of human skeletal muscle to acute bouts of resistance exerciseJournal of Applied Physiology, 2005
- Age differences in knee extension power, contractile velocity, and fatigabilityJournal of Applied Physiology, 2005
- Myostatin Mutation Associated with Gross Muscle Hypertrophy in a ChildNew England Journal of Medicine, 2004
- Activins, Myostatin and Related TGF-β Family Members as Novel Therapeutic Targets for Endocrine, Metabolic and Immune DisordersCurrent Drug Target - Immune, Endocrine & Metabolic Disorders, 2004